CYP2D6 - MHRA Correspondence

Earlier this year I corresponded with Sarah Morgan, Group Manager of Pharmacovigilance Risk Management Group at the MHRA.

Basically, I wanted to learn about the CYP2D6 issue as it is a particularly grey area for me.

A series of emails was sent between Sarah and I has now been made public here

A recent thread on Paxil Progress, listed as, 'Paroxetine is a potent inactivator of CYP2D6?' has created much debate. The author of the thread, has basically cut and paste information without offering opinion.

It should come as no surprise that the author of the thread is Jeremy Bryce.

One reader writes:

"Jeremy, you are quoting press releases from pharmaceutical companies. Statements in press releases may be inaccurate. Phase I trials are nothing. They are prologues to marketing campaigns so companies can raise money for research. You are mistaking promotional material for fact. "What is going on" is that Concert Pharma is trying to drum up business.

When you post this type of material without cross-checking it, you alarm people unnecessarily."

The thread can be viewed here


Fid

ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING